BCIQ Profiles

Company Profile ReportTarget Profile Report

Biogen, Eisai discontinuing aducanumab studies in AD

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more pressure on Biogen to add to its Phase III pipeline.

The companies

Read the full 468 word article

How to gain access

Continue reading with a
two-week free trial.